Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 186
- Registration Number
- NCT06705478
- Locations
- 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
🇺🇸UCSD Antiviral Research Center CRS, San Diego, California, United States
Escitalopram in Asthma Patients with Frequent Exacerbation
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 105
- Registration Number
- NCT06216535
- Locations
- 🇺🇸
1440 Empire Central, Ste. LD4.100, Dallas, Texas, United States
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 418
- Registration Number
- NCT05973786
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- KRL Hospital, Islamabad
- Target Recruit Count
- 744
- Registration Number
- NCT05950061
- Locations
- 🇵🇰
KRL Hospital, Islamabad, Pakistan
Development and Application of Comprehensive Intervention Techniques for Adolescent Depression
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 100
- Registration Number
- NCT05945342
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 1254
- Registration Number
- NCT05603104
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 336
- Registration Number
- NCT05536414
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Austin, Texas, United States
Home Transcutaneous Electrical Acustimulation (TEA)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 160
- Registration Number
- NCT05519683
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Peking University
- Target Recruit Count
- 252
- Registration Number
- NCT05389046
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
🇨🇳Beijing Huilongguan Hospital, Beijing, Beijing, China
🇨🇳Beijing Xicheng District Pingan Hosptial, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.